Delhi – India’s Central Drugs Standard Control Organisation (CDSCO) said on Thursday that 112 drug samples tested during September were found to be “Not of Standard Quality” (NSQ). The finding is part of the regulator’s regular monthly drug alert that helps keep the market safe.
Out of the 112 samples flagged as NSQ, 52 were identified by Central Drugs Laboratories (CDL) while State Drugs Testing Laboratories (SDTL) added 60 more. The CDSCO’s portal now lists those samples each month so consumers and professionals can see which products do not meet the required standards.
“For September 2025, Central Drugs Laboratories identified 52 drug samples as NSQ and State Drugs Testing Laboratories identified 60 drug samples as NSQ,” the alert read. The lab marks a product as NSQ when it fails one or more of the quality parameters set by the regulator. Importantly, a failure in a batch does not mean all other batches of that medicine are unsafe; it only flags that specific sample.
In addition to the NSQ findings, the alert reported a single “spurious” drug discovered in Chhattisgarh. The medicine was produced by an unauthorised manufacturer using a brand name owned by a different company. The case is under investigation and the CDSCO says authorities will take action under the applicable act and rules.
The CDSCO works with state regulators every month to detect, list, and remove NSQ and spurious medicines from the market. This is part of a broader regulatory surveillance effort designed to protect patients.
For reference, in August the regulator flagged 94 drug samples as NSQ – 32 from CDL and 62 from SDTL – showing a steady effort to keep Indian pharmaceuticals compliant with safety and quality standards.
Source: ianslive
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
